RARE – Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.RARE
$22.79Name : Ultragenyx Pharmaceutical Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $2,244,569,600.00
EPSttm : -6.1
Ultragenyx Pharmaceutical Inc.
$22.79
5.56%$1.20
RARE — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
15.59
Margin Of Safety %
Put/Call OI Ratio
0.64
EPS Next Q Diff
0.59
EPS Last/This Y
1.59
EPS This/Next Y
5.21
Price
22.79
Target Price
52.05
Analyst Recom
1.32
Performance Q
-0.22
Upside
-1,038.4%
Beta
0.4
Ticker: RARE
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-05-11 | RARE | 26.32 | 0.86 | 0.35 | 32595 |
| 2026-05-12 | RARE | 26.85 | 0.86 | 0.83 | 32812 |
| 2026-05-13 | RARE | 26.44 | 0.86 | 0.02 | 32808 |
| 2026-05-14 | RARE | 25.8 | 0.86 | 0.01 | 32812 |
| 2026-05-15 | RARE | 24.99 | 0.90 | 0.07 | 31736 |
| 2026-05-18 | RARE | 24.16 | 0.70 | 0.85 | 21066 |
| 2026-05-19 | RARE | 22.49 | 0.70 | 1.18 | 21242 |
| 2026-05-20 | RARE | 23.38 | 0.71 | 0.09 | 21535 |
| 2026-05-21 | RARE | 23.7 | 0.70 | 0.87 | 21616 |
| 2026-05-22 | RARE | 23.38 | 0.70 | 0.97 | 21659 |
| 2026-05-26 | RARE | 23.15 | 0.72 | 0.35 | 23647 |
| 2026-05-27 | RARE | 23.38 | 0.73 | 0.42 | 23705 |
| 2026-05-28 | RARE | 23.25 | 0.73 | 1.23 | 23692 |
| 2026-05-29 | RARE | 23.93 | 0.72 | 0.50 | 23670 |
| 2026-06-02 | RARE | 21.79 | 0.64 | 0.74 | 29101 |
| 2026-06-03 | RARE | 22.43 | 0.64 | 0.07 | 29220 |
| 2026-06-04 | RARE | 23.31 | 0.64 | 0.03 | 29204 |
| 2026-06-05 | RARE | 21.92 | 0.64 | 0.08 | 29168 |
| 2026-06-08 | RARE | 21.6 | 0.64 | 0.05 | 29148 |
| 2026-06-09 | RARE | 22.79 | 0.64 | 0.30 | 29162 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-05-11 | RARE | 26.32 | 2.8 | - | -4.46 |
| 2026-05-12 | RARE | 26.84 | -4.5 | - | -4.59 |
| 2026-05-13 | RARE | 26.45 | -4.3 | - | -4.67 |
| 2026-05-14 | RARE | 25.79 | -4.3 | - | -4.67 |
| 2026-05-15 | RARE | 24.99 | -4.4 | - | -4.61 |
| 2026-05-18 | RARE | 24.18 | -4.4 | - | -4.61 |
| 2026-05-19 | RARE | 22.45 | -4.4 | - | -4.61 |
| 2026-05-20 | RARE | 23.37 | -4.6 | - | -4.57 |
| 2026-05-21 | RARE | 23.70 | -4.6 | - | -4.57 |
| 2026-05-22 | RARE | 23.38 | -4.6 | - | -4.57 |
| 2026-05-26 | RARE | 23.14 | 2.3 | - | -4.24 |
| 2026-05-27 | RARE | 23.39 | 2.3 | - | -4.24 |
| 2026-05-28 | RARE | 23.24 | 2.3 | - | -4.24 |
| 2026-05-29 | RARE | 23.93 | 2.3 | - | -4.24 |
| 2026-06-01 | RARE | 22.86 | 2.3 | - | -4.24 |
| 2026-06-02 | RARE | 21.78 | 2.3 | - | -4.24 |
| 2026-06-03 | RARE | 22.42 | 2.3 | - | -4.24 |
| 2026-06-04 | RARE | 23.29 | 2.3 | - | -4.24 |
| 2026-06-05 | RARE | 21.91 | 2.3 | - | -4.24 |
| 2026-06-08 | RARE | 21.60 | 2.3 | - | -4.24 |
| 2026-06-09 | RARE | 22.79 | 2.3 | - | -4.24 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-05-11 | RARE | -2.24 | -3.66 | 13.03 |
| 2026-05-12 | RARE | -2.24 | -3.66 | 14.73 |
| 2026-05-13 | RARE | -2.24 | -3.66 | 14.73 |
| 2026-05-14 | RARE | -2.24 | -3.66 | 14.73 |
| 2026-05-15 | RARE | -2.24 | -3.66 | 14.73 |
| 2026-05-18 | RARE | -2.24 | -4.50 | 14.73 |
| 2026-05-19 | RARE | -2.34 | -4.50 | 14.73 |
| 2026-05-20 | RARE | -2.34 | -4.50 | 14.73 |
| 2026-05-21 | RARE | -2.34 | -4.50 | 14.73 |
| 2026-05-22 | RARE | -2.34 | -4.50 | 14.73 |
| 2026-05-26 | RARE | -2.34 | 5.68 | 15.24 |
| 2026-05-27 | RARE | -1.52 | 5.68 | 15.24 |
| 2026-05-28 | RARE | -1.52 | 5.68 | 15.59 |
| 2026-05-29 | RARE | -1.52 | 5.68 | 15.59 |
| 2026-06-02 | RARE | -1.57 | 4.82 | 15.59 |
| 2026-06-03 | RARE | -1.57 | 4.82 | 15.59 |
| 2026-06-04 | RARE | -1.57 | 4.82 | 15.59 |
| 2026-06-05 | RARE | -1.57 | 4.82 | 15.59 |
| 2026-06-08 | RARE | -1.57 | 4.75 | 15.59 |
| 2026-06-09 | RARE | -1.57 | 4.75 | 15.59 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.54
Avg. EPS Est. Current Quarter
-1.14
Avg. EPS Est. Next Quarter
-0.95
Insider Transactions
-1.57
Institutional Transactions
4.75
Beta
0.4
Average Sales Estimate Current Quarter
181
Average Sales Estimate Next Quarter
183
Fair Value
Quality Score
71
Growth Score
47
Sentiment Score
20
Actual DrawDown %
78.4
Max Drawdown 5-Year %
-82
Target Price
52.05
P/E
Forward P/E
PEG
P/S
3.35
P/B
P/Free Cash Flow
EPS
-6.11
Average EPS Est. Cur. Y
-4.24
EPS Next Y. (Est.)
0.97
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-91.03
Relative Volume
0.88
Return on Equity vs Sector %
230.6
Return on Equity vs Industry %
246.7
EPS 1 7Days Diff
0.4
EPS 1 30Days Diff
0.22
EBIT Estimation
◆
RARE
Healthcare
$22.79
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
46.4
Range 1M
27.1%
Sup Dist
6.9%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
23.1%
EPS NY
84.4%
52W%
19.5%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+71.7% upside
Upside
+71.7%
Quality
71
Ultragenyx Pharmaceutical Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 1371
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.
RARE
Latest News
—
Caricamento notizie per RARE…
stock quote shares RARE – Ultragenyx Pharmaceutical Inc. Stock Price stock today
news today RARE – Ultragenyx Pharmaceutical Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RARE – Ultragenyx Pharmaceutical Inc. yahoo finance google finance
stock history RARE – Ultragenyx Pharmaceutical Inc. invest stock market
stock prices RARE premarket after hours
ticker RARE fair value insiders trading